AbbVie, a global biopharmaceutical firm, and Lupin Limited, recently revealed their collaboration. They announced that AbbVie has approved Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program. Through this collaboration, AbbVie will get the exclusive worldwide opportunity to manufacture and sale Lupin’s MALT1 inhibitors.
MALT-1 is a protein engaged in B-cell and T-cell lymphocyte activation. AbbVie aims to practice development across a variety of hematological cancers. Currently, numerous of these diseases are with restricted treatment choices. Nilesh Gupta, Managing Director, Lupin Limited, proclaimed the firm is extremely proud to be able to bring novel treatments to needy patients. He added that the firm is pleased to collaborate with AbbVie who share a commitment to bring superior class medicines in regions with a shortage of standard treatment and have an awful medical need.
On a similar note, recently, AbbVie came into the news as it revealed that it has filed a new drug application (NDA) to the FDA. At the same time, the firm also revealed that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA). Both these applications are related to upadacitinib, an oral trial JAK inhibitor from the firm. The firm is looking for upadacitinib’s approval. It will be used in treating patients with moderate to serious rheumatoid arthritis (RA).
The regulatory submissions were founded on data from the phase III SELECT research, which studied over 4000 patients across five phase III researches on RA. In all the researches, upadacitinib was successful in meeting all primary and secondary endpoints. Data from the SELECT research demonstrated that treatment using upadacitinib, both as a monotherapy and in a blend with traditional synthetic DMARDs, led to improved signs of RA, superior physical function, and reticent radiographic progression.